Latest operating income for NERV: $-20B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Minerva Neurosciences (NERV) currently reports a operating income of $-20B as of September 2026. That compares with $-2.8T in the prior-year period — up 99.3% year over year. Use the charts on this page to explore Minerva Neurosciences's operating income history and peer comparisons.
Minerva Neurosciences's operating income increased from $-2.8T to $-20B — a 99.3% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Minerva Neurosciences reported $-20B in operating income as of September 2026. That compares with $-2.8T in the prior-year period — up 99.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $-20B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Minerva Neurosciences, and consider following NERV for alerts when major investors trade the stock.
Minerva Neurosciences is classified in the Healthcare sector. On operating income, it currently shows $-20B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NERV with unrelated industries.